๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers Clinical trials Hanzhou
Clinical trial register · China

Clinical Trials in Hanzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Hangzhou 373 Huzhou 16 Ningbo 15 Shanghai 13 Hanzhou 13
Narrow the registerReset
Recruitment status
Phase
Site location
Hangzhou373 Huzhou16 Ningbo15 Shanghai13 Hanzhou13
All 69 locations
Target enrolment
to

Trials with a site in Hanzhou

13 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
the Study of the Association Between the Gut Microbiota and Central Serous Chorioretinopathy
NCT06527326Central Serous Chorioretinopathy
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
400
Hanzhou
2026-05-27
Recruiting
A Study of Pomadomide in Combination With Rituximab and Methotrexate for Newly-diagnosed Primary Central Nervous System Lymphoma
NCT06554561PCNSL
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 1/2
43
Hanzhou
2024-08-31
Recruiting
A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT06554600Refractory or Relapsed Diffuse Large B Cell Lymphoma
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
36
Hanzhou
2024-08-31
Recruiting
A Study of Selinexor in Combination With Temozolomide and Anti-PD-1 Antibody in Patients With Relapsed/Refractory Primary Central Nervous System Lymphoma
NCT06556199Relapsed/Refractory Primary Central Nervous System Lymphoma
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 1/2
38
Hanzhou
2024-08-31
Recruiting
Application of an Early In-Hospital Temperature Management Protocol for Heat Stroke Patients
NCT06537557Heat Stroke
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
188
Guli, Dongyang, Hanzhou, Jinhua, Lanxi, Yiwu
2024-07-01
Recruiting
the Multi-modal Evaluation of Agitation in Critically Ill Patients Based on Remote Video-Ultra-sensitive Detection Wave
NCT06543602Critically Ill Patients
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
580
Hangzhou, Hanzhou
2024-05-01
Not yet open
Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer
NCT05841849Breast Cancer, Chemotherapy-induced Nausea and Vomiting
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
1,028
Hanzhou
2023-07
Recruiting
Efficacy of Supplement Adjuvant Capecitabine in HR+/HER2- Breast Cancer Patients With High Risks
NCT05212454Breast Cancer, Chemotherapy Effect
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 3
400
Hanzhou
2023-03-15
Recruiting
Orelabrutinib,Rituximab and Methotrexate in Newly Diagnosed Primary Central Nervous System Lymphoma
NCT05600660Primary Central Nervous System Lymphoma
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
28
Hanzhou
2022-08-01
Recruiting
Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL
NCT05472558B-cell Non Hodgkin Lymphoma
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 1
48
Hanzhou
2022-07-26
Recruiting
Regional or Extend LymphAdenectomy During Resection of Intrahepatic Cholangiocarcinoma
NCT04078230Intrahepatic Cholangiocarcinoma
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
168
Beijing, Guangzhou, Changsha, Hohhot, Shanghai, Xiโ€™an, Chengdu, Hanzhou
2020-01-01
Recruiting
Application of Radiomics in Breast Cancer
NCT04483804Breast Cancer, Ultrasound, Elastography, Pathology
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
2,000
Hanzhou
2018-01-01
Recruiting
Transcatheter Aortic Valve Replacement Single Center Registry in Chinese Population
NCT02803294Symptomatic Aortic Stenosis
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 4
2,000
Hanzhou
2016-06
Rows per page Showing 1–13 of 13
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/hanzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 13 of those studies with a site in Hanzhou that also match the filters currently applied.

How many clinical trials are recruiting in Hanzhou?

12 of the 13 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 1 have not yet opened recruitment, 0 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Hanzhou), 13 studies
PhaseStudiesRecruitingShare
Not applicable3323.1%
Observational2215.4%
Phase 1/22215.4%
Phase 22215.4%
Phase 42115.4%
Phase 1117.7%
Phase 3117.7%

Most active sponsors

Lead sponsors with the most studies (Hanzhou)
Lead sponsorStudiesRecruiting
Second Affiliated Hospital, Zhejiang University, School of Medicine1312
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.